Hypersensitivity

(Redirected from Hypersensitive)
Jump to: navigation, search
Hypersensitivity
ICD-10 T78.4
ICD-9 995.3
DiseasesDB 28827
MeSH D006967

WikiDoc Resources for Hypersensitivity

Articles

Most recent articles on Hypersensitivity

Most cited articles on Hypersensitivity

Review articles on Hypersensitivity

Articles on Hypersensitivity in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hypersensitivity

Images of Hypersensitivity

Photos of Hypersensitivity

Podcasts & MP3s on Hypersensitivity

Videos on Hypersensitivity

Evidence Based Medicine

Cochrane Collaboration on Hypersensitivity

Bandolier on Hypersensitivity

TRIP on Hypersensitivity

Clinical Trials

Ongoing Trials on Hypersensitivity at Clinical Trials.gov

Trial results on Hypersensitivity

Clinical Trials on Hypersensitivity at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hypersensitivity

NICE Guidance on Hypersensitivity

NHS PRODIGY Guidance

FDA on Hypersensitivity

CDC on Hypersensitivity

Books

Books on Hypersensitivity

News

Hypersensitivity in the news

Be alerted to news on Hypersensitivity

News trends on Hypersensitivity

Commentary

Blogs on Hypersensitivity

Definitions

Definitions of Hypersensitivity

Patient Resources / Community

Patient resources on Hypersensitivity

Discussion groups on Hypersensitivity

Patient Handouts on Hypersensitivity

Directions to Hospitals Treating Hypersensitivity

Risk calculators and risk factors for Hypersensitivity

Healthcare Provider Resources

Symptoms of Hypersensitivity

Causes & Risk Factors for Hypersensitivity

Diagnostic studies for Hypersensitivity

Treatment of Hypersensitivity

Continuing Medical Education (CME)

CME Programs on Hypersensitivity

International

Hypersensitivity en Espanol

Hypersensitivity en Francais

Business

Hypersensitivity in the Marketplace

Patents on Hypersensitivity

Experimental / Informatics

List of terms related to Hypersensitivity

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Hypersensitivity refers to undesirable (damaging, discomfort-producing and sometimes fatal) reactions produced by the normal immune system. Hypersensitivity reactions require a pre-sensitized (immune) state of the host. The four-group classification was expounded by P. H. G. Gell and Robin Coombs in 1963.[1]

Comparison table

Comparison of hypersensitivity types
Type Alternative names [2] Often mentioned disorders[2] Mediators[2]
1 Allergy
2 Cytotoxic, antibody-dependent
3 Immune complex disease
4 cell-mediated

Type 1 - immediate (or atopic, or anaphylactic)

Type 1 hypersensitivity is an allergic reaction provoked by reexposure to a specific type of antigen referred to as an allergen.[3] Exposure may be by ingestion, inhalation, injection, or direct contact. The difference between a normal immune response and a type I hypersensitive response is that plasma cells secrete IgE. This class of antibodies binds to Fc receptors on the surface of tissue mast cells and blood basophils. Mast cells and basophils coated by IgE are "sensitized." Later exposure to the same allergen, cross-links the bound IgE on sensitized cells resulting in degranulation and the secretion of pharmacologically active mediators such as mastcell , leukotriene, and prostaglandin that act on the surrounding tissues. The principal effects of these products are vasodilation and smooth-muscle contraction.

The reaction may be either local or systemic. Symptoms vary from mild irritation to sudden death from anaphylactic shock. Treatment usually involves epinephrine, antihistamines, and corticosteroids. If the entire body gets involved, then anaphylaxis can take place; an acute, systemic reaction that can prove fatal.

Some examples:

Type 2 - antibody-dependent

In type 2 hypersensitivity, the antibodies produced by the immune response bind to antigens on the patient's own cell surfaces. The antigens recognized in this way may either be intrinsic ("self" antigen, innately part of the patient's cells) or extrinsic (absorbed onto the cells during exposure to some foreign antigen, possibly as part of infection with a pathogen). These cells are recognised by macrophages or dendritic cells which act as antigen presenting cells, this causes a B cell response where antibodies are produced against the foreign antigen.

An example here is the reaction to penicillin where the drug can bind to red blood cells causing them to be recognised as different, B cell proliferation will take place and antibodies to the drug are produced. IgG and IgM antibodies bind to these antigens to form complexes that activate the classical pathway of complement activation for eliminating cells presenting foreign antigens (which are usually, but not in this case, pathogens). That is, mediators of acute inflammation are generated at the site and membrane attack complexes cause cell lysis and death. The reaction takes hours to a day.

Another form of type 2 hypersensitivity is called antibody-dependent cell-mediated cytotoxicity (ADCC). Here, cells exhibiting the foreign antigen are tagged with antibodies (IgG or IgM). These tagged cells are then recognised by natural killer (NK) cells and macrophages (recognised via IgG bound (via the Fc region) to the effector cell surface receptor, CD16 (FcγRIII)), which in turn kill these tagged cells.

Some examples:

Type 3 - immune complex

Type 3 hypersensitivity occurs when antigens and antibodies are present in roughly equal amounts, causing extensive cross-linking. Large immune complexes that cannot be cleared are deposited in vessel walls and induce an inflammatory response. The reaction can take hours, days, or even weeks to develop.

Some clinical examples:

Type 4 - cell-mediated (delayed-type hypersensitivity, DTH)

See also: Cell mediated immunity

Type 4 hypersensitivity is often called delayed type as the reaction takes two to three days to develop. Unlike the other types, it is not antibody mediated but rather is a type of cell-mediated response.

CD8+ cytotoxic T cells and CD4+ helper T cells recognise antigen in a complex with either type 1 or 2 major histocompatibility complex. The antigen-presenting cells in this case are macrophages which secrete IL-12, which stimulates the proliferation of further CD4+ T cells. CD4+ T cells secrete IL-2 and interferon gamma, further inducing the release of other Type 1 cytokines, thus mediating the immune response. Activated CD8+ T cells destroy target cells on contact while activated macrophages produce hydrolytic enzymes and, on presentation with certain intracellular pathogens, transform into multinucleated giant cells.

Some clinical examples:

Type 5 - stimulatory

This is an additional type that is sometimes (often in Britain) used as a distinction from Type 2.[4]

Instead of binding to cell surface components, the antibodies recognize and bind to the cell surface receptors, which either prevents the intended ligand binding with the receptor or mimics the effects of the ligand, thus impairing cell signalling.

Some clinical examples:

(There is also a type 6 hypersensitivity reaction in which natural killer cells lyse cells that have been coated in antibody and this reaction is thought to be implicated with certain autoimmune diseases, tumour rejection & parasite rejection).


Causes

Causes by Organ System

Cardiovascular No underlying causes
Chemical/Poisoning No underlying causes
Dental No underlying causes
Dermatologic No underlying causes
Drug Side Effect Ado-trastuzumab emtansine, Aminohippurate, Amoxicillin, Aprotinin, Artemether/lumefantrine, Asparaginase, Aspirin, Azficel-T, Bepotastine Besilate, Bicalutamide, Blinatumomab, Boceprevir, Butalbital, Conestat alfa, Cytarabine, Desmopressin, Dexpanthenol, dibucaine, Ecallantide, Elosulfase alfa, Epirubicin , ferumoxytol, Flutemetamol F 18, Fluoxymesterone, gadoxetate, Gallium Citrate Ga 67, Goserelin, hexaminolevulinate, Human rabies virus immune globulin, hydroxyethyl starch, Hydroxyprogesterone caproate, Interferon alfa-2b , interferon alfacon-1, Ixabepilone, Levoleucovorin, Lomefloxacin hydrochloride, Meropenem, Metaproterenol, Methylene blue, Netupitant and palonosetron, Oritavancin, Paclitaxel, Phenobarbital, Piperacillin/tazobactam, Rimabotulinumtoxinb, Sacrosidase, Sorafenib, Sulfasalazine, Oprelvekin, Penicillin G potassium, Pertuzumab, Sulfacetamide, Teniposide, tuberculin, Trimethobenzamide, Vedolizumab, Umeclidinium.
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic No underlying causes
Genetic No underlying causes
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease No underlying causes
Musculoskeletal/Orthopedic No underlying causes
Neurologic No underlying causes
Nutritional/Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic No underlying causes
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy No underlying causes
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous No underlying causes

Causes in Alphabetical Order

See also

References

  1. Gell PGH, Coombs RRA, eds. Clinical Aspects of Immunology. 1st ed. Oxford, England: Blackwell; 1963.
  2. 2.0 2.1 2.2 Unless else specified in boxes, then ref is: Lippincott's Illustrated Reviews: Immunology. Paperback: 384 pages. Publisher: Lippincott Williams & Wilkins; (July 1, 2007). Language: English. ISBN-10: 0781795435. ISBN-13: 978-0781795432. Page 195
  3. med/1101 at eMedicine
  4. Rajan TV. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol. 2003 Jul;24(7):376-9. PMID 12860528

External links

de:Überempfindlichkeitsreaktion no:Hypersensitivitet vec:Clasificaxion de Gell e Coombs



Linked-in.jpg